Issouf Soro

In silico Design of Sulfenylated 5-Aminopyrazole Derivatives, Novel Butyrylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease

Issouf Soro, Manchondenin Soro, Ludovic Akonan, Niaré Adama, Boris Davy Bekono, Raymond Kre N’guessan & Eugene Megnassan · Asian Journal of Chemical Sciences · 2026

Alzheimer’s disease (AD) is a neurodegenerative disorder associated with cholinergic dysfunction, and butyrylcholinesterase (BuChE) becomes increasingly relevant as disease pathology progresses. This study aimed to design sulfenylated 5-aminopyrazole (APS) analogues as potential...

Open access Research Article 10.9734/ajocs/2026/v16i5478

Design and In silico Screening of Combinatorial Library of New Herbicidal Analogs of Cycloalka[d]quinazoline-2,4dione−Benzoxazinones Inhibiting Protoporphyrinogen IX Oxidase

Hermann N’Guessan, Issouf Soro, Melalie Keita & Eugene Megnassan · Journal of Pharmaceutical Research International · 2022

We virtually design here an important new weedkiller Cycloalka[d]quinazoline-2,4dione−Benzoxazinones (CQB), inhibitors of Protoporphyrinogen IX Oxidase (PPO). Based on computer-assisted combinatorial chemistry techniques, docking, 3D-QSAR and pharmacophore models we first enumera...

Open access Research Article 10.9734/jpri/2022/v34i567251

Computer-Aided Design of Imidazo [4.5-c] Pyridin-4-one Derivatives as Antagonists of the Angiotensin II Type 1 (AT1) Receptor

Abel Landry Tebily, Akoun Abou, Issouf Soro, Abdoulaye Djandé, Niaré Adama & Megnassan Eugène · Journal of Pharmaceutical Research International · 2026

Over the past decade, drug resistance has emerged as a major challenge in the treatment of high blood pressure. This report evaluates new imidazo[4.5-c]pyridin-4-one compounds designed to inhibit the AT1 enzyme, and highlights their therapeutic potential, supported by favourable...

Open access Research Article 10.9734/jpri/2026/v38i57837